Search

Your search keyword '"Kaden B. Rawson"' showing total 2 results
Start Over Author "Kaden B. Rawson"
2 results on '"Kaden B. Rawson"'

1. Ex vivo comparison of V.A.C.® Granufoam Silver™ and V.A.C.® Granufoam™ loaded with a first-in-class bis-dialkylnorspermidine-terphenyl antibiofilm agent

Author

Kaden B. Rawson, Travis Neuberger, Tyler B. Smith, Isaac J. Bell, Ryan E. Looper, Paul R. Sebahar, Travis J. Haussener, Hariprasada Reddy Kanna Reddy, Brad M. Isaacson, John Shero, Paul F. Pasquina, and Dustin L. Williams

Subjects
Biofilm, Negative pressure wound therapy, MRSA, A. baumannii, Biotechnology, TP248.13-248.65, Microbiology, QR1-502
Abstract

Implementation of negative pressure wound therapy (NPWT) as a standard of care has proven efficacious in reducing both the healing time and likelihood of nosocomial infection among pressure ulcers and traumatic, combat-related injuries. However, current formulations may not target or dramatically reduce bacterial biofilm burden following therapy. The purpose of this study was to determine the antibiofilm efficacy of an open-cell polyurethane (PU) foam (V.A.C.® Granufoam™) loaded with a first-in-class compound (CZ-01179) as the active release agent integrated via lyophilized hydrogel scaffolding. An ex vivo porcine excision wound model was designed to perform antibiofilm efficacy testing in the presence of NPWT. PU foam samples loaded with a 10.0% w/w formulation of CZ-01179 and 0.5% hyaluronic acid were prepared and tested against current standards of care: V.A.C.® Granufoam Silver™ and V.A.C.® Granufoam™. We observed statistically significant reduction of methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii biofilms with the CZ-01179 antibiofilm foam in comparison to current standard of care foams. These findings motivate further development of an antibiofilm PU foam loaded with CZ-01179.

Published
2023
Full Text
View/download PDF

2. Antibiofilm potential of a negative pressure wound therapy foam loaded with a first‐in‐class tri‐alkyl norspermidine‐biaryl antibiotic

Author

Kaden B. Rawson, Travis Neuberger, Tyler Smith, Hariprasada Reddy Kanna Reddy, Travis J. Haussener, Paul R. Sebahar, Ryan E. Looper, Brad M. Isaacson, John Shero, Paul F. Pasquina, and Dustin L. Williams

Subjects
Methicillin-Resistant Staphylococcus aureus, Biomaterials, Spermidine, Biofilms, Biomedical Engineering, Negative-Pressure Wound Therapy, Anti-Bacterial Agents
Abstract

Negative-pressure wound therapy (NPWT) is commonly utilized to treat traumatic injuries sustained on the modern battlefield. However, NPWT has failed to decrease the incidence of deep tissue infections experienced by Wounded Warriors, despite attempts to integrate common antimicrobials, like Ag+ nanoparticles, into the wound dressing. The purpose of this study was to incorporate a unique antibiofilm compound (CZ-01179) into the polyurethane matrix of NPWT foam via lyophilized hydrogel scaffolding. Foam samples with 2.5%, 5.0%, and 10.0% w/w CZ-01179 were produced and antibiofilm efficacy was compared to the current standards of care: V.A.C.® GRANUFOAM SILVER™ and V.A.C.® GRANUFOAM™. Gravimetric analysis and elution kinetics testing confirmed that this loading technique was both repeatable and controllable. Furthermore, zone of inhibition and antibiofilm efficacy testing showed that foam loaded with CZ-01179 had significantly increased activity against planktonic and biofilm phenotypes of methicillin-resistant Staphylococcus aureus and Acinetobacter baumannii compared to the clinical standards. These findings motivate additional ex vivo and in vivo work with NPWT foam loaded with CZ-01179 with the overall objective of reducing NPWT-associated infections that complicate battlefield-related and other wounds.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results